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number of days in the lunar month (which is used 
in the Moslem  calendar) and the number of letters 
in the Arabic alphabet. Nonetheless, the evident 
erudition of Moselm  doctors compared to their 
western counterparts was so great that the more 
progressive of Christian physicians appreciated what 
w as translated from their writings. Chaucer's Doctor 
of Physick has no less than six Moslem s in his list 
of authorities:
“Well know he the old Esculapius,
And Dioscorides, and else Rufus;
Old Hippocras, Hali, and Gallien;
Serapion, Rasis, and Avicen;
Avarrois, Dam ascene and Constantin;
Bernard, and Gatisden, and Gilbertin”.
Little wonder that Christian rulers who were in 
close communication with neighbouring Islamic 
states, as in partitioned Spain and in the Crusader- 
ruled Holy Land, used to send to the Moslem s when 
they wanted a good physician!
I have attempted to give a brief outline of the 
debt our current medical practice owes to the great 
doctors of classical Islam, and in conclusion I can­
not do better than quote from Meyerhof’s  authorita­
tive work "The  Legacy of Islam " —
"Looking back we may say that Islamic medicine 
and science reflected the light of the Hellenic sun 
when its day had fled, and that they shone like a 
moon, illuminating the darkest night of the European 
Middle Ages: that some bright stars lent their own 
light, and that moon and stars alike faded at the 
dawn of a new day —  the Renaissance. Since they 
had their share in the direction and introduction of 
that great movement, it may reasonably be claimed 
that they are with us yet”.
NOTE:
For those who wish to follow up this subject the 
writings of Edward Browne are recommended, who 
qualified in medicine, turned to Middle Eastern 
studies and went on to become Professor of Arabic 
at Cambridge. His scholarly work “Arabian 
Medicine" (C.U.P. 1921) is available from the Cen­
tral Medical Library. The quotations in this article 
come from various sources and are translated either 
by Browne or by A. J. Arberry, the present Pro­
fessor of Arabic to Cambridge University.
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Until about 1957 it was generally accepted that 
the regulation of renal sodium excretion was depend­
ent solely upon changes in
(a) glomerular filtration rate (Factor 1) and
(b) the activity of the renin-angiotensin-aldosterone 
system (Factor 2).
coupled with the effect of changes in intrarenal 
haemodynamics and physical factors, such as hydro­
static pressure surrounding renal tubules, and 
plasma protein osmotic pressure in peritubular 
capillaries.
Since that time, however, evidence has gradually 
been accumulated to suggest that these are not the 
only factors which are relevant in this context, and 
the existence of a humoral inhibitor of renal sodium 
reabsorption has therefore been postulated. This 
‘third factor' has been given the name of natriuretic 
hormone, and indications of its presence have been 
found in two principal situations. These are
(a) 'Sodium  escape’ during chronic mineralo- 
corticoid administration
(b) Volume expansion with (i) isotonic saline
(ii) blood
‘Sodium escape’ during chronic mineralo- 
corticoid administration
When the extracellular fluid volume was expanded 
in healthy humans or dogs by chronic mineralo-
corticoid administration, an initial diminution of 
sodium excretion resulted, followed within a few 
days by a rise to control levels (2, 37). This 
‘sodium escape phenomenon' was attributed as early 
as 1957 to the existence of a circulating natriuretic 
hormone (37).
The presence of such a hormone was for some 
time disputed as many potential natriuretic factors 
have been identified during 'sodium escape ' from 
chronic mineralocorticoid treatment. Other natrieu- 
retic factors include deceased plasma renin con­
centrations, increased glomerular filtration rate and 
increased renal plasma flow. Sodium escape has, 
however, been shown to occur in the absence of 
each of these variables, thus indicating that none 
of them is critical to the escape mechanism (see 8).
Recently, additional evidence for the existence of 
a circulating natriuretic hormone has been provided 
by Buckalew and Lancaster in 1972 (8). They 
demonstrated the presence of a substance with 
natriuretic activity in ultrafiltrates of jugular venous 
plasma when ‘sodium escape ' occurred in dogs 
undergoing chronic administration of deoxycorti­
costerone acetate (DO CA ).
Volume expansion with isotonic saline
There is much evidence to suggest that when the 
blood volume of an animal is expanded with isotonic 
saline, the rise in urinary sodium excretion which
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occurs is due, in part, to a change in the concentra­
tion of a circulating hormone other than aldosterone.
The release of such a circulating natriuretic 
hormone was postulated by de Wardener et al, in 
1961 (43). They demonstrated that in dogs receiv­
ing high concentrations of vasopressin and mineralo- 
corticoid hormones, an intravenous infusion of 
isotonic saline produced a rise in urinary sodium 
excretion even when the glomerular filtration rate 
was deliberately lowered by inflating a balloon in the 
thoracic aorta. A natriuresis also occurred in de- 
nervated and isolated kidneys perfused with blood 
from volume expanded animals. The tubular re- 
absorption of sodium must therefore have decreased, 
and this decrease must have been caused by some 
mechanism other than a fall in the concentration of 
aldosterone. Similar experiments and cross-perfusion 
(19) experiments involving volume expansion with 
isotonic saline have confirmed these results (see 
42).
An interesting experiment was devised by Richet 
and Hornych (32). They saline-loaded rats, and 
demonstrated that sodium reabsorption was in­
hibited both in the renal tubules and in a piece of 
the in vivo perfused Jejunum in each rat. Aldo 
sterone pretreatment of the rats had no influence on 
this phenomenon. Since the two epithelial struc­
tures, which have common histological and 
immunological characteristics, were far apart, a 
natriuretic mechanism extrinsic to the kidney was 
postulated. They suggested that the natriuresis 
could have been mediated by a circulating hormone.
Volume expansion with blood
More precise evidence for the existence of a 
natriuretic hormone has been obtained from experi­
ments in which the blood volume of animals was 
expanded with blood that was already in equilibrium 
with their own blood. Thus, haemodilution which is 
itself a natriuretic factor was excluded. A natriuresis 
was obtained using this method of volume expansion 
not only in whole animals but also in isolated 
kidneys perfused with blood from volume expanded 
animals. The volume expanded animals were 
treated with maximal doses of vasopressin and 
mineralocorticoid hormone and a natriuresis could 
be obtained even when the glomerular filtration rate 
was lowered (3, 20, 26, 39).
An elaborate experiment was performed by 
Tobian et al. (39) in which an isolated rat kidney 
was perfused with blood at a constant pressure 
(Fig.1). The kidney’s only connexion with the rat 
which supplied it with blood was the blood itself. 
When a quantity of a mixture of two parts blood and 
one part Ringer’s solution was placed into the 
venous reservoir without expanding the blood 
volume of the rat, there was no increase in sodium 
excretion by the isolated kidney (Fig. 1). When the 
same quantity of the mixture was infused intra­
venously into the rat and the blood volume ex­
panded, there was in most instances a large rise in 
sodium excretion from the isolated kidney. This 
natriuresis was associated with a rise in renal blood 
flow and glomerular filtration rate. Since the rise in 
sodium excretion could not be attributed to haemo­
dilution, renal nerve stimulation or a rise in arterial 
blood pressure, it was concluded that its cause 
must be a change in the concentration of a circul­
ating substance which simultaneously increased 
renal blood flow by producing renal vasodilatation.
Fig. 1 Method used tor determ ining the effect on 
urinary sodium excretion in an isolated rat kidney, 
of either d ilu ting the blood or expanding the blood  
volume of the donor rat. The kidneys and adrenals 
were removed in the donor rat. (Tobian, Coffee and 
McCrea, 1967).
Further evidence for the existence of a 
circulating natriuretic hormone
This has been obtained from the detection of 
natriuretic activity in samples of plasma and urine. 
These sampes were collected from volume ex­
panded man and animals, and humans with various 
clinical conditions. Natriuretic activity has been 
detected in the following —
(1) Plasma from saline-loaded dogs, rats, cats, 
sheep and cows (7, 9, 12, 31, 35) and plasma 
from dogs whose blood volume was expanded 
with blood (11, 30).
(2) Plasma and urine from intravenously saline- 
loaded normal man and man on a high salt diet 
(10, 35, 36, 41); Also urine from orally water 
loaded humans (22).
(3) Plasma and urine collected before and after 
saline loading of patients with primary aldo­
steronism (35, see 36).
(4) Plasma and urine from saline loaded patients 
with essential hypertension (35).
(5) Serum from uraemic patients (6, 7).
(6) Plasma from dogs during nephron reduction 
(7).
(7) Plasma from dogs (on a constant sodium in­
take) during ‘sodium escape' as a result of 
chronic mineralocorticoid treatment (8).
Natriuertic activity has not however been detected 
in plasma and urine samples from humans on a 
low salt diet (35) or in urine collected from water 
loaded patients with congestive heart failure (22).
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Assay preparations for the detection of 
natriuretic activity
Many in vivo and in vitro assay preparations have 
been developed for the detection of natriuretic 
activity in samples of plasma or urine. These are 
summarized below.
in vivo preparations
In most cases (6, 22, 35, 36, 41) the plasma and 
urine samples were concentrated and fractionated 
(using dialysis and ultrafiltration). Natriuretic 
activity was then detected in the samples by inject­
ing or infusing them into assay rats and observing 
changes in urine flow and in sodium and potassium 
excretion from the bladder or ureters. The assay 
rats used in the different laboratories were under 
varying conditions of salt and water intake, and the 
samples were injected intravenously, intra-aortically, 
subcutaneously or directly into a renal artery.
Natriuretic activity has also been detected in un­
concentrated plasma or dialysed plasma samples 
when they were injected directly into a renal tubule 
of an assay rat with hereditary diabetes insipidus. 
The rate at which the proximal tubular reabsorption 
of sodium was inhibited by the samples was deter­
mined by micropuncture (shrinking-drop technique) 
and by clearance techniques (31).
In vitro preparations
The transport of sodium, potassium and p-amino- 
hippuric acid (PAH) has been studied in renal 
tubuls fragments which have been incubated in 
vitro both in untreated plasma (11) and in con­
centrated and fractionated urine (10) taken from 
man and animals before and after blood volume 
expansion. When incubated in plasma or urine 
obtained after volume expansion, tubule fragments 
were less able to maintain a constant gradient of 
sodium and potassium, or to accumulate PAH than 
when incubated in control plasma.
Blood from blood volume expanded dogs inhibited 
the transepithelial transport of sodium by the isolated 
frog skin (30). Similarly, this preparation was used 
to detect natriuretic activity in concentrated and 
fractionated samples of uraemic serum (6).
Concentrated and fractionated plasma samples 
from saline loaded dogs, or dogs in which 
‘sodium escape’ from chronic mineralocorticoid 
administration had occurred, inhibited toad bladder 
sodium transport (9).
Mode of action of natriuretic hormone
When natriuretic activity was detected in samples 
of plasma and urine using in vivo assay prepara­
tions, the natriuresis was accompanied by an in­
creased renal blood flow, a factor which itself pro­
duces a natriuresis. From these experiments, it 
was, therefore, impossible to determine whether 
the postulated natriuretic hormone acted by a direct 
action on renal tubular sodium transport. The sub­
sequent use of in vitro assay preparations for the 
detection of natriuretic hormone showed, however, 
that the hormone directly inhibited the cellular 
mechanisms for active sodium transport.
Thus, it is probable that natriuretic hormone acts 
in vivo both by directly inhibiting tubular sodium 
transport and by producing renal vasodilatation.
Site of action of natriuretic hormone
Micropuncture techniques .have revealed that the
fall in sodium reabsorption with volume expansion 
takes place in the proximal tubules (14, 31). 
Proximal tubular sodium reabsorption is also in­
hibited when the sodium escape' phenomenon 
develops in more prolonged experiments in which 
the extra cellular fluid volume has been expanded 
by the administration of mineralocorticoids (44).
It has been reported that the distal tubule plays 
no regulatory role in the control of sodium excretion 
(5, 42). However, once proximal tubular sodium 
reabsorption has been maximally depressed during 
the administration of a saline load, the rate of 
sodium excretion can still be increased (13). Thus, 
the inhibition of sodium reabsorption in the distal 
segments of the nephron is also important in regul­
ating sodium excretion during saline loading, and 
natriuretic hormone may act in these segments (13, 
34, 35).
Source of natriuretic hormone
Many ablational experiments have been performed 
in an attempt to locate the source of the proposed 
natriuretic hormone. Many of these experiments 
were misleading as saline administration to animals 
produces a fall in plasma protein osmotic pressure 
and usually a rise in arterial blood pressure. Both 
of these changes evoke a natriuresis even in an 
isolated kidney perfused by a heart lung preparation. 
Thus, it is not surprising that the administration of 
saline to a decapitated dog with the adrenals, liver 
spleen removed, still produced a natriuresis (25).
Ablational experiments should, therefore, be per­
formed using animals expanded with whole blood 
or blood with which their own blood is in equilibrium. 
Such an experiment, which was described earlier 
in this article, has been performed by Tobian et al., 
(39: see Fig 1). They suggested it was unlikely 
that natriuretic hormone was released from the 
adrenals or kidneys. Other workers have variously 
reported that natriuretic hormone could (19) and 
could not (33) be derived from the kidney. The 
liver (29, 38) and the brain (1, 12, 27, 37) have also 
been suggested as the source of the hormone. The 
origin of natriuretic hormone still remains uncertain.
Nature of natriuretic hormone
As a result of various attempts to detect natriuretic 
activity in plasma and urine samples, various reports 
as to the nature and properties of natriuretic hor­
mone have resulted.
From studies using dialysis and gel filtration, the 
hormone has been reported to be non-dialysable 
and to have a molecular weight between 5,000 and 
70,000 (35, 36). Other workers reported that the 
hormone was dialysable and had a molecular weight 
of less than 1,000 (6, 10, 12, 31). These conflict­
ing results could readily be obtained if natriuretic 
hormone was a small molecule which was bound to 
a larger molecule (e.g. a plasma protein). In addi­
tion, natriuretic hormone has been variously reported 
to be a protein (35, 36), a polypeptide (12), to be 
resistant to boiling (6, 12, 35, 36) and to be stable 
only in the cold (31).
The natriuretic activity detected in some extracts 
displayed a delay in onset of up to one hour after 
injection and the effect lasted for up to three hours 
(35, 36). Again, these properties could suggest that 
natriuretic hormone was a small molecule which was 
slowly released from binding to a larger molecule. 
Other workers (31) however, found that their 
natriuretic material was rapid in onset (seconds),
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with a short duration of action (less than thirty 
minutes). The hormone, which was effective on 
intravenous, intra-arterial or direct intratubular in­
jection, has been reported to act primarily on sodium 
excretion and rarely to increase urine flow (31, 35, 
36) but another report suggested that the hormone 
was more diuretic than natriuretic (12). The 
hormone produced an increase in renal blood flow 
35, 36) but no change in potassium excretion or 
glomerular filtration rate. Natriuretic activity has 
been detected in both arterial and venous blood 
(31, 35, 36) but some workers were only able to 
detect the hormone in plasma samples which were 
concenrated before assay (6, 9, 10, 22, 31, 35, 36) 
whereas others detected it in blood or unconcen­
trated plasma (11, 12, 30, 31).
Some of the conflicting properties attributed to 
natriuretic hormone may result from the presence 
of contaminants in the plasma and urine extracts. 
Such contaminants could have been introduced 
during the concentration and fractionation pro­
cedures. In addition, bacterial endotoxins in urine 
samples have been shown to produce a potent 
natriuresis in assay animals (see Discussion after 
36).
Natriuretic hormone and prostaglandins
It has been suggested that a prostaglandin could 
be a circulating (28) or intrarenal natriuretic 
hormone (23). Prostaglandins are a group of natur­
ally occuring 20-carbon fatty acids which contain a 
cyclopentane ring and are derivatives of prostanoic
Fig. 2
acid (Fig. 2). Five series of naturally occurring 
prostaglandins have so far been described; namely 
the A, B, C, E and F series, all of which exhibit 
structural differences in the ring (Fig.3). The pro­
staglandins possess a wide variety of pharmaco­
logical actions (18).
Fig. 3
Prostaglandins of the A and E series have been 
shown to produce a natriuresis and diuresis in 
dogs and rabbits when infused in very low concen­
trations either intra-aortically or directly into a renal 
artery (17, 28, 40, Davis, unpublished). Prostag­
landin A1 produces a natriuresis when infused intra- 
aoretically in concentrations as low as 0.001 and 
0.6 nanograms per millilitre of arterial blood in 
dogs and rabbits, respectively. Since prostaglandins 
of the A series (unlike the E series) are not meta­
bolised by the lungs, they also produce a natriuresis 
when infused intravenously in similar concentrations,
and they could be capable of acting as circulating 
natriuretic hormones (28).
It has also been proposed that prostaglandins of 
the A and E series could be intrarenal natriuretic 
hormones, as prostaglandins A2, E2 and F2a have 
been identified in the renal medulla of the rabbit, 
dog and rat (see 23). Lee (23) has suggested that 
when the extracellular fluid volume is increased, 
prostaglandins A2 and E2 could be released from 
the renal medulla to circulate intrarenally (possibly 
via the vasa rectae or lymph) to the renal cortex 
where they could stimulate a natriuresis. This 
theory is supported by the observations that the 
enzymes responsible for the synthesis of prostag­
landins exist in the renal medulla, whereas the 
enzymes responsible for their degradation have been 
detected in high concentrations in the renal cortex 
and not the medulla (see 23 . However, it is also 
possible that during volume expansion, prosta­
glandin A2 could be released from the renal medulla 
into the renal venous blood, circulate and then 
produce a natriuresis by an action in the renal 
cortex.
The natriuresis produced by prostaglandins and 
by natriuretic hormone is accompanied by vaso­
dilatation in the renal cortex and an increase in 
renal blood flow. There is a redistribution of intra­
renal blood flow from the medulla to the cortex. 
Glomerular filtration rate remains unchanged or 
increases slightly (see 23). It is not known whether 
prostaglandins stimulate a natriuresis in vivo solely 
by producing vasodilatation in the renal cortex, 
or whether they also exert a direct action on renal 
tubular sodium transport (16).
Since natriuretic hormone has been detected in 
samples of peripheral venous plasma, either a 
prostaglandin of the A series could have been de­
tected or there is another circulating natriuretic 
hormone which either acts directly in the kidney to 
produce a natriuresis or stimulates the intrarenal 
release of prostaglandins of the A and E series.
Natriuretic hormone has also been detected in 
urine samples. Recently, prostaglandins E1, E2 
and F2x have been identified in female human 
urine but no search was made for prostaglandins 
of the A series (15). Natriuretic activity in urine 
samples could, therefore, be attributable to the pre­
sence of prostaglandins of the E and possibly the 
A series.
Since the circulating concentration of prostag­
landin A1 or A2 required to produce a natriuresis is 
very low and these prostaglandins are unstable in 
blood, no evidence for the release and circulation 
of these prostaglandins, during blood volume ex­
pansion, has yet been obtained (Davis, un­
published).
Clinical implications of natriuretic hormone
Natriuretic hormone has been associated with 
several clinical conditions, namely uraemia, aldo­
steronism, and congestive heart failure.
Uraemia
Since a natriuretic humoral substance was de­
tected in the serum of uraemic patients, it was 
suggested by Bricker et al., (6, 7) that this 
hormone could serve in a homoeostatic role to in­
crease the rate of sodium excretion per nephron 
as the number of nephrons diminished in advancing 
renal disease. Using experimental animals with 
nephron reduction, it has previously been shown
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that the progressive natriuresis per nephron cannot 
be explained by a decrease in mineralocorticoid 
hormone activity, a change in glomerular filtration 
rate per nephron or by such physical factors as a 
change in cardiac output, mean arterial blood pres­
sure, peripheral resistance or filtration fraction (see 
6). It was also suggested (6) that in advanced 
renal disease, very high levels of natriuretic hor­
mone could lead to the inhibition of sodium trans­
port in extrarenal organs and contribute to the 
symptoms of the uraemic state.
Aldosteronism
Natriuretic activity was detected in extracts of 
urine and plasma samples collected, before saline 
loading, from patients with primary aldosteronism, 
but no such activity was detected in similar extracts 
from normal healthy humans (see 36). In addition, 
higher concentrations of natriuretic activity were 
detected in plasma and urine samples collected 
from saline loaded patients with primary aldoster­
onism than from normal humans (35, see 36). It is 
possible that in patients with primary aldosteronism, 
the enhanced basal and stimulated levels of circul­
ating natriuretic hormone were released in order 
to offset excessive renal sodium retention produced 
by increased concentrations of aldosterone. This 
possibility is supported by the demonstration of a 
circulating natriuretic hormone in venous plasma 
taken from dogs during ‘sodium escape' from 
chronic mineralocorticoid treatment (8).
Congestive heart failure
Krück (22) demonstrated that extracts of urine 
from orally water loaded humans possessed natriur­
etic activity, whereas similar extracts from water 
loaded patients with congestive heart failure 
possessed no such activity. He therefore suggested 
that an insufficiency or lack of natriuretic hormone 
in patients with congestive heart failure, could be 
an explanation for the increased renal tubular 
sodium reabsorption and development of oedema in 
cardiac disease.
Summary
A considerable amount of evidence has now been 
accumulated to support the existence of a circul­
ating natriuretic hormone. Natriuretic activity has 
been demonstrated in plasma and urine samples 
collected during volume expansion with isotonic 
saline or blood, the administration of a high salt 
diet, ‘sodium escape' during chronic mineralo­
corticoid administration and in certain clinical con­
ditions. Under these conditions natriuretic hormone 
is released in detectable concentrations, but lower 
amounts of the hormone may be released continu­
ally, to participate in the regulation of sodium 
excretion. The chemical nature of the hormone still 
remains unknown, but a prostaglandin of the A 
series could be intrarenal natriuretic hormones.
ITEM OF MEDICAL INTEREST
The next day, as Candide was walking out, he 
met a beggar all covered in sores, his eyes were 
sunk in his head, the end of his nose eaten off, his 
mouth drawn to one side, his teeth as black as a 
coal, snuffling and coughing most violently, and 
every time he attempted to spit, out dropt a tooth.
(This was none other than Candide’s old tutor, 
who described how he came to this state in these 
words)
"O my dear Candide, you must remember 
Pacquette, that pretty wench, who waited on our 
noble baroness; in her arms I tasted the pleasures 
of paradise, which produced these hell-torments 
with which you see me devoured. She was infected 
with the disease, and perhaps is since dead of it; 
she received this present from a learned cordelier, 
he was indebted for it to an old countess, who had 
it of a captain of horse, who had it of a marchioness, 
who had it of a page, the page had it of a Jesuit 
who, during his noviate had it from one of the 
fellow-adventurers of Christopher Columbus. For 
my part I shall give it to no-body for I am a dying 
man.”
From Voltaire's ‘‘Candide’', published in 1759.
THERAPEUTICS PROBLEM
A man attending an anti-coagulant clinic as an 
out-patient occasionally has unacceptably short pro­
thrombin times. He claims to have been taking his 
tablets with religious regularity. He is rather sur­
prised when the Doctor asks him what type of cook­
ing oil his wife uses. Is this a relevant question? 
Answer on page 14.
Editor’s note —  A list of references provided by 
Dr. Davis is available from the Society's office.
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